Skip to content

Effects of the hallucinogenic beverage ayahuasca on voluntary ethanol intake by rats and on cFos expression in brain areas relevant to drug addiction

Luciana Marangni Nolli, Danilo Gustavo Rodrigues de Oliveira, Stefany Sousa Alves, Marcus Vinicius von Zuben, Aline Pic‐taylor, Márcia Renata Mortari, Eloísa Dutra Caldas

Alcohol November 4, 2019 DOI: 10.1016/j.alcohol.2019.10.005 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Animal experiment Peer reviewed
Population Wistar rats
Interventions Ayahuasca Naltrexone
Dose 0.5x, 1x, or 2x the ritual dose for ayahuasca; 2 mg/kg body weight for naltrexone
Duration 8-week ethanol access, 5-day treatment period
Topics Addiction Ayahuasca
Keywords Nucleus accumbens Ethanol Endocrinology Cortex anatomy Hallucinogen Pharmacology Central nervous system Biochemistry
Citations 28
Key findings Ayahuasca at 0.5x, 1x, or 2x the ritual dose did not decrease ethanol intake in rats, but the lowest dose reduced cFos expression in the medial orbital cortex to levels comparable to a naïve group.

Abstract

Ayahuasca is a hallucinogenic infusion used in religious rituals that has serotoninergic properties and may be a potential therapeutic option for drug addiction. In this study, Wistar rats had intermittent access to ethanol for 8 weeks, receiving water (control), naltrexone (NTX, 2 mg/kg body weight [bw] intraperitoneally [i.p.]) or ayahuasca (Aya) at 0.5x, 1x, or 2x the ritual dose in the final 5 days. A naïve group had access only to water. Ethanol intake was estimated throughout the experiment, and cFos expression was evaluated in medial orbital cortex (MO), ventral orbital cortex (VO), lateral orbital cortex (LO), nucleus accumbens (NAc), and striatum. Treatment with either NTX or Aya (oral) did not decrease ethanol intake compared to the baseline level (5th to 7th week), but the NTX group intake was significantly lower than controls (p < 0.05). Ethanol significantly increased cFos expression in the MO region for control (p < 0.0001), NTX (p < 0.05), Aya1 (p < 0.001), and Aya2 (p < 0.0001) groups. This increase was also observed in the VO for the Aya1 group (p = 0.035), in the LO for the Aya2 group (p < 0.01), and in NAc for NTX and ayahuasca groups (p < 0.005). Furthermore, NTX and Aya0.5 treatment decreased cFos expression compared to controls in the MO region (p < 0.05 and p < 0.01, respectively), but only the ayahuasca group reached levels not significantly different from the naïve group. Studies using other protocols and dose regime are necessary to better investigate the impact of ayahuasca on alcohol intake by rats to support the observations in humans. Additionally, the role of ayahuasca in mediating cFos expression in other selected brain regions and its relationship with the serotoninergic/dopaminergic systems and drug addiction need further investigation.

Explore topics